Summit Seeks Shareholder Approval to Double Authorized Shares for AstraZeneca Conversion
SMMT sits 43% above its 52-week low of $12.07.
Summary
Summit Therapeutics is seeking shareholder approval to double its authorized common stock to 2 billion shares, a move required to satisfy the conversion terms of AstraZeneca's $2 billion preferred stock investment that closed October 5, 2026.
Key Events · Corporate Governance and Compliance · SMMT
-
Charter Amendment to Double Authorized Shares
Proposal 1 seeks to increase authorized common stock from 1,000,000,000 to 2,000,000,000 shares. As of October 1, 2026, Summit had 799,726,418 shares outstanding and only 66,727,073 authorized, unreserved shares available.
-
AstraZeneca Conversion Requires Additional Shares
The $2 billion AstraZeneca private placement (closed October 5, 2026) issued preferred stock convertible into 108,955,369 common shares. Summit currently lacks sufficient authorized shares to permit full conversion.
-
Redemption Risk if Amendment Fails
If the Required Increase Amendment is not effective by April 5, 2028, Summit must redeem all outstanding Class A Preferred Stock for cash at then-prevailing market value — a significant potential cash obligation.
-
Going Concern Warning Reiterated
The proxy states that failure to approve the amendment may prevent Summit from accessing capital markets and could negatively affect its ability to continue as a going concern.
Analysis · SMMT · Life Sciences
Summit Therapeutics is asking shareholders to approve a charter amendment doubling authorized common stock from 1 billion to 2 billion shares. The vote is contractually required by the $2 billion AstraZeneca private placement that closed on October 5, 2026 — the preferred shares convert into 108,955,369 common shares, but Summit currently has only 66.7 million authorized, unreserved shares available. Without approval, Summit cannot satisfy its conversion obligation and would face a mandatory cash redemption of the preferred stock by April 5, 2028. The filing also confirms the company's going-concern risk: failure to approve could prevent future capital raises and negatively affect its ability to continue as a going concern.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 29.4% of the 1563 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SMMT was trading at $17.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.8B. The 52-week trading range was $12.07 to $29.23. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.